Skip to content

AngioDynamics

US · ANGO #3631 by market cap
10.81 +0.05 +0.46%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:01

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions increased by 8 in the most recent period (2026/Q3).
  • Total institutional ownership fell 1.1 percentage points.

Ownership vs. money flow

Diverging

Institutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
92.03% -1.10pp
Institutions
210 +8
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund58.13%
Hedge Fund28.89%
Individual/Insider9.60%
Public Company2.78%
Insurance Company1.11%
Private Company0.53%
Government Pension Fund0.44%
Family Office/Trust0.12%

Top holders as of 2026-09-30

BlackRock 9.63% · 4.05M sh
Point72 Asset Management, L.P. 7.28% · 3.06M sh
Systematic Financial Management LP 6.28% · 2.64M sh
Kevin Kotler 5.76% · 2.42M sh
Armistice Capital LLC 5.23% · 2.20M sh
Royce & Associates, LP 4.57% · 1.92M sh
Broadfin Capital, LLC 4.32% · 1.82M sh
Vanguard Capital Management, LLC 4.07% · 1.71M sh
Weber Capital Management, LLC 3.21% · 1.35M sh
Teachers Insurance and Annuity Association-College Retirement Equities Fund 2.60% · 1.10M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 31 buys · 19 sells

NameRoleStake
James Clemmer Former Chief Executive Officer 1.20%
Howard Donnelly Independent Non-Executive Chairperson 0.43%
Wesley Johnson Independent Director 0.36%
Stephen Trowbridge Chief Financial Officer 0.32%
Jan Reed Independent Director 0.28%
Eileen Auen Independent Director 0.28%
Karen Licitra Independent Director 0.24%
Michael Tarnoff Independent Director 0.23%
Laura Piccinini Senior VP & GM of International 0.20%
Lorinda Burgess Independent Director 0.16%
Chad Campbell Senior VP and GM of Oncology & Interventional Devices 0.15%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-01 Eric Honroth Chief Executive Officer Other Acquisition +101,193 --
2026-11-01 Eric Honroth Chief Executive Officer Other Derivative Acquisition +62,928 --
2026-10-28 Stephen Trowbridge Chief Financial Officer Open Market Disposition -25,335 $12.17–12.27
2026-07-29 Warren Nighan Senior Vice President of Regulatory Affairs, Quality & Global Supply Chain Open Market Disposition -23,370 $14.72
2026-07-21 Warren Nighan Senior Vice President of Regulatory Affairs, Quality & Global Supply Chain Derivative Exercise and Sale -1,671 $13.82
2026-07-21 Warren Nighan Senior Vice President of Regulatory Affairs, Quality & Global Supply Chain Derivative Exercise and Retained +4,023 --
2026-07-21 James Clemmer Former Chief Executive Officer Derivative Exercise and Sale -26,728 $13.82
2026-07-21 James Clemmer Former Chief Executive Officer Derivative Exercise and Retained +25,630 --
2026-07-21 Stephen Trowbridge Chief Financial Officer Derivative Exercise and Sale -8,319 $13.82
2026-07-21 Stephen Trowbridge Chief Financial Officer Derivative Exercise and Retained +7,977 --
2026-07-21 Laura Piccinini Senior VP and GM of Cardiovascular & International Derivative Exercise and Sale -4,506 $13.82
2026-07-21 Laura Piccinini Senior VP and GM of Cardiovascular & International Derivative Exercise and Retained +3,541 --
2026-07-21 Chad Campbell Senior VP and GM of Oncology & Interventional Devices Derivative Exercise and Sale -2,330 $13.82
2026-07-21 Chad Campbell Senior VP and GM of Oncology & Interventional Devices Derivative Exercise and Retained +4,136 --
2026-07-19 Warren Nighan Senior Vice President of Regulatory Affairs, Quality & Global Supply Chain Sale to Issuer -3,777 $13.51–14.14
2026-07-19 James Clemmer Former Chief Executive Officer Sale to Issuer -45,711 $13.51–14.14
2026-07-19 Stephen Trowbridge Chief Financial Officer Sale to Issuer -12,067 $13.51–14.14
2026-07-19 Laura Piccinini Senior VP and GM of Cardiovascular & International Sale to Issuer -8,228 $13.51–14.14
2026-07-19 Chad Campbell Senior VP and GM of Oncology & Interventional Devices Sale to Issuer -3,838 $13.51–14.14
2026-07-15 Lawrence Weiss Chief Legal Officer Sale to Issuer -2,267 $14.14

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 20:01:15 · For reference only, not investment advice and not tailored to your situation.

AngioDynamics discussion 0 comments

Add a comment